MX2022013010A - Composiciones y metodos para inhibir la expresion genica de lpa. - Google Patents

Composiciones y metodos para inhibir la expresion genica de lpa.

Info

Publication number
MX2022013010A
MX2022013010A MX2022013010A MX2022013010A MX2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A
Authority
MX
Mexico
Prior art keywords
lpa
gene expression
compositions
methods
rnai
Prior art date
Application number
MX2022013010A
Other languages
English (en)
Inventor
Darren H Wakefield
David B Rozema
David L Lewis
Aaron Almeida
Lauren J Almeida
Stacey Melquist
Steven Kanner
Vladimir S Trubetskoy
Tao Pei
Zhen Li
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MX2022013010A publication Critical patent/MX2022013010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.
MX2022013010A 2015-10-01 2018-03-27 Composiciones y metodos para inhibir la expresion genica de lpa. MX2022013010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02

Publications (1)

Publication Number Publication Date
MX2022013010A true MX2022013010A (es) 2022-11-09

Family

ID=58424351

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003833A MX2018003833A (es) 2015-10-01 2016-09-30 Composiciones y metodos para inhibir la expresion genica de lpa.
MX2022013010A MX2022013010A (es) 2015-10-01 2018-03-27 Composiciones y metodos para inhibir la expresion genica de lpa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003833A MX2018003833A (es) 2015-10-01 2016-09-30 Composiciones y metodos para inhibir la expresion genica de lpa.

Country Status (36)

Country Link
US (4) US9932586B2 (es)
EP (2) EP4029941A1 (es)
JP (5) JP6991966B2 (es)
KR (3) KR102728481B1 (es)
CN (1) CN108368506A (es)
AU (3) AU2016331084B2 (es)
CA (1) CA3000397A1 (es)
CL (1) CL2018000803A1 (es)
CO (1) CO2018003678A2 (es)
CR (1) CR20180231A (es)
CY (1) CY1125263T1 (es)
DK (1) DK3356529T3 (es)
EA (1) EA038478B1 (es)
ES (1) ES2896298T3 (es)
HR (1) HRP20211410T1 (es)
HU (1) HUE055942T2 (es)
IL (3) IL258333B (es)
JO (2) JOP20160211B1 (es)
LT (1) LT3356529T (es)
MA (1) MA43347B1 (es)
MX (2) MX2018003833A (es)
MY (1) MY195796A (es)
PE (1) PE20181139A1 (es)
PH (1) PH12018500713A1 (es)
PL (1) PL3356529T3 (es)
PT (1) PT3356529T (es)
RS (1) RS62523B1 (es)
SG (1) SG10202008530TA (es)
SI (1) SI3356529T1 (es)
SM (1) SMT202100622T1 (es)
TN (1) TN2018000094A1 (es)
TW (4) TWI836693B (es)
UA (1) UA121998C2 (es)
UY (1) UY36926A (es)
WO (1) WO2017059223A2 (es)
ZA (1) ZA202106265B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
US10246709B2 (en) * 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
TN2020000039A1 (en) * 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PE20201287A1 (es) * 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
US11110180B2 (en) 2017-10-04 2021-09-07 Avidity Biosciences Inc. Nucleic acid-polypeptide compositions and uses thereof
JP7473472B2 (ja) * 2017-10-17 2024-04-23 アローヘッド ファーマシューティカルズ インコーポレイテッド アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
CA3081905C (en) * 2017-11-13 2023-10-03 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
IL281597B1 (en) * 2018-09-19 2026-05-01 Arrowhead Pharmaceuticals Inc RNAI agents for suppressing 17 beta-HSD type 13 expression, (HASD17B13), their compositions and uses
PH12021550801B1 (en) * 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
CA3142283A1 (en) * 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
AU2020399636A1 (en) * 2019-12-09 2022-06-02 Amgen Inc. RNAi constructs and methods for inhibiting LPA expression
JP2023519215A (ja) * 2020-03-23 2023-05-10 アムジエン・インコーポレーテツド 化学修飾核酸に対するモノクローナル抗体及びその使用
TW202535432A (zh) 2020-08-05 2025-09-16 美商戴瑟納製藥股份有限公司 抑制lpa表現之組合物及方法
JP2023545502A (ja) * 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
CA3199678A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
US20250034561A1 (en) * 2021-02-18 2025-01-30 Oneglobe Holdings Limited Novel Compositions for Conjugating Oligonucleotides and Carbohydrates
EP4355756A4 (en) 2021-06-18 2025-08-13 Hongene Biotech Corp N-ACETYLGALACTOSAMINE FUNCTIONALIZED NUCLEOSIDES
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
EP4402263A2 (en) 2021-09-14 2024-07-24 Argonaute Rna Limited Treatment of cardiovascular disease
CN116801886B (zh) * 2021-09-18 2024-12-06 成都心正合医药科技有限公司 Lpa抑制剂及其用途
WO2023088227A1 (zh) 2021-11-16 2023-05-25 上海舶望制药有限公司 抑制血管紧张素原(agt)蛋白表达的组合物和方法
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
CN118076738A (zh) * 2021-12-16 2024-05-24 上海拓界生物医药科技有限公司 靶向LPA的siRNA及缀合物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
JP2025526074A (ja) * 2022-08-11 2025-08-07 エピジェニック・セラピューティクス・プライベイト・リミテッド エピトープ編集標的のための方法およびその使用
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
KR20250130686A (ko) * 2023-01-13 2025-09-02 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
WO2024210530A1 (en) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. RNAi AGENTS TARGETING LPA GENE AND USE THEREOF
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
TW202509024A (zh) 2023-05-19 2025-03-01 大陸商深圳信立泰藥業股份有限公司 一種磺醯胺類化合物及其製備方法和醫藥用途
CN119343449A (zh) * 2023-05-24 2025-01-21 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024280186A1 (en) 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
CN121752721A (zh) * 2023-05-31 2026-03-27 箭头药业股份有限公司 用于多聚体RNAi剂缀合物的肝脏递送平台及其使用方法
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (en) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
WO2025119212A1 (zh) * 2023-12-05 2025-06-12 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
WO2026092650A1 (zh) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 一种抑制LPA基因表达的RNAi制剂及其应用
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8658211B2 (en) 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
BRPI0715375A2 (pt) 2006-08-18 2013-06-18 Hoffmann La Roche policonjugados para distribuiÇço in vivo de polinucleotÍdeos
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
EP3023495B1 (en) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
BR112013013434A2 (pt) * 2010-12-17 2016-08-16 Arrowhead Res Corp metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
NZ611656A (en) 2010-12-29 2014-10-31 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
MY167390A (en) * 2011-11-18 2018-08-16 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
AU2012377385A1 (en) 2012-04-18 2014-01-23 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
HUE051680T2 (hu) * 2012-05-24 2021-03-29 Ionis Pharmaceuticals Inc Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
HK1219422A1 (zh) * 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
CA2921162A1 (en) * 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2015021092A1 (en) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
SG10202105989WA (en) 2015-05-29 2021-07-29 Arrowhead Pharmaceuticals Inc Compositions and methods for inhibiting gene expression of hif2alpha
JP6896703B2 (ja) * 2015-07-31 2021-06-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
US10246709B2 (en) 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds

Also Published As

Publication number Publication date
US20200263179A1 (en) 2020-08-20
IL258333B (en) 2022-03-01
UY36926A (es) 2017-04-28
IL290566B2 (en) 2023-07-01
US20170096665A1 (en) 2017-04-06
LT3356529T (lt) 2021-12-27
MA43347A (fr) 2018-08-08
WO2017059223A9 (en) 2017-08-17
IL290566B1 (en) 2023-03-01
EA038478B1 (ru) 2021-09-03
TWI880645B (zh) 2025-04-11
US10662427B2 (en) 2020-05-26
EP3356529B1 (en) 2021-08-25
TW202449154A (zh) 2024-12-16
JOP20210043A1 (ar) 2021-03-08
CR20180231A (es) 2018-05-31
BR112018006489A2 (pt) 2018-10-09
KR102942707B1 (ko) 2026-03-23
TWI836693B (zh) 2024-03-21
MY195796A (en) 2023-02-21
MA43347B1 (fr) 2021-11-30
US20250115907A1 (en) 2025-04-10
DK3356529T3 (da) 2021-11-08
TW202600825A (zh) 2026-01-01
JP2022113835A (ja) 2022-08-04
US9932586B2 (en) 2018-04-03
NZ780687A (en) 2025-06-27
IL300438A (en) 2023-04-01
SMT202100622T1 (it) 2022-01-10
JP7442574B2 (ja) 2024-03-04
HRP20211410T1 (hr) 2021-12-24
JP7116212B2 (ja) 2022-08-09
WO2017059223A3 (en) 2017-05-11
JP2021087459A (ja) 2021-06-10
CA3000397A1 (en) 2017-04-06
TWI784934B (zh) 2022-12-01
JOP20160211B1 (ar) 2021-08-17
AU2016331084A1 (en) 2018-04-19
KR102728481B1 (ko) 2024-11-12
EP3356529A2 (en) 2018-08-08
TN2018000094A1 (en) 2019-07-08
PL3356529T3 (pl) 2021-12-20
KR20180052703A (ko) 2018-05-18
EP3356529A4 (en) 2019-09-04
CL2018000803A1 (es) 2018-08-31
AU2016331084B2 (en) 2022-09-08
ES2896298T3 (es) 2022-02-24
SI3356529T1 (sl) 2022-01-31
JP6991966B2 (ja) 2022-02-03
IL290566A (en) 2022-04-01
KR20260046241A (ko) 2026-04-06
US20180195070A1 (en) 2018-07-12
AU2022283623A1 (en) 2023-02-02
PH12018500713A1 (en) 2018-10-15
CN108368506A (zh) 2018-08-03
JP2018529732A (ja) 2018-10-11
EA201890864A1 (ru) 2018-09-28
IL300438B1 (en) 2026-03-01
PT3356529T (pt) 2021-11-04
NZ741086A (en) 2023-11-24
KR20240162596A (ko) 2024-11-15
CO2018003678A2 (es) 2018-11-30
HK1259063A1 (en) 2019-11-22
AU2022283623B2 (en) 2025-07-10
HUE055942T2 (hu) 2022-01-28
AU2025242219A1 (en) 2025-10-23
RS62523B1 (sr) 2021-11-30
EP4029941A1 (en) 2022-07-20
TW201726918A (zh) 2017-08-01
UA121998C2 (uk) 2020-08-25
TW202332769A (zh) 2023-08-16
WO2017059223A2 (en) 2017-04-06
IL258333A (en) 2018-05-31
ZA202106265B (en) 2023-08-30
JP2024009262A (ja) 2024-01-19
PE20181139A1 (es) 2018-07-17
SG10202008530TA (en) 2020-10-29
CY1125263T1 (el) 2023-03-24
JP2026040461A (ja) 2026-03-09
MX2018003833A (es) 2018-06-18

Similar Documents

Publication Publication Date Title
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
MX2017011422A (es) Composiciones y metodos para inhibir la expresion del gen del factor xii.
MX2020010524A (es) Composiciones y metodos para inhibir la expresion del gen de alfa-1 antitripsina.
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX368056B (es) Compuestos tricíclicos inhibidores de atr (cinasa de ataxia telangiectasia mutada y rad-3.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
AR106227A1 (es) COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA)
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)